LIPOVELA-V

Product Overview

LIPOVELA-V, also written as LIPO VELA-V, is a South Korean lipolytic solution marketed for professional facial contouring applications. Its formulation combines phosphatidylcholine (PPC), sodium deoxycholate, L-carnitine, glutathione, vitamins, and multiple peptide-based ingredients. The product is commonly supplied in 5 mL vials, with ten vials per box, providing a total nominal volume of 50 mL.

LIPOVELA-V is positioned within the medical aesthetics market for facial contour refinement, particularly applications involving the appearance of fullness around the chin and jawline. Its formulation combines ingredients associated with adipocyte membrane disruption and cellular lipid metabolism with additional compounds commonly used in skin-conditioning products.

The product's published brochure presents this combination under the concept of V-Line Contour and Glutathione Whitening. This describes its commercial positioning rather than independently established clinical effectiveness for facial fat reduction, skin whitening, or tissue regeneration.

This TEOSQUARE product page provides professional buyers with information about LIPOVELA-V's composition, ingredient characteristics, packaging specifications, and important regulatory considerations.

Key Features

• PPC + Sodium Deoxycholate: Combines phosphatidylcholine with sodium deoxycholate, a bile salt with established membrane-disrupting properties relevant to research on injectable adipocytolysis.
• L-Carnitine and Vitamin B Complex: Includes L-carnitine and vitamins B2, B3, and B12, ingredients involved in normal cellular metabolism and related biochemical pathways.
• Glutathione-Containing Formulation: Incorporates glutathione, a naturally occurring tripeptide involved in cellular antioxidant defense, alongside other skin-conditioning ingredients.
• Growth Factor and Peptide Components: Published composition information identifies EGF, FGF, IGF, and cosmetic peptides, including Acetyl Hexapeptide-8 and Palmitoyl Pentapeptide-4.
• 5 mL Vial Presentation: The documented commercial packaging contains ten 5 mL vials, providing 50 mL of solution per box.

Composition & Specifications

LIPOVELA-V is a multi-ingredient liquid formulation containing phosphatidylcholine, sodium deoxycholate, glutathione, L-carnitine, vitamins, and several peptide-related components.

The published product brochure identifies PPC and sodium deoxycholate as principal ingredients. It describes the raw materials as having a purity of 99%, but these purity figures must not be interpreted as the final concentrations of the ingredients in the finished solution.

Phosphatidylcholine (PPC)

Phosphatidylcholine is a naturally occurring phospholipid consisting of a glycerol backbone, fatty acid chains, and a phosphocholine head group. It is a major component of biological membranes and participates in lipid transport and metabolism.

PPC has historically been investigated as a component of localized fat-reduction formulations, particularly in combination with sodium deoxycholate. However, research indicates that the membrane-disrupting effects of these combinations are substantially associated with deoxycholate.

The LIPOVELA-V product brochure reports PPC at 1,000 mg and identifies 99% raw material purity. The brochure does not clearly establish whether the stated mass applies to an individual vial, an entire package, or another formulation reference quantity.

Sodium Deoxycholate

Sodium deoxycholate is the sodium salt of deoxycholic acid, a secondary bile acid naturally present in the human body.

Its amphipathic molecular structure gives it detergent-like properties, allowing it to interact with lipid membranes. At sufficient concentrations, sodium deoxycholate can compromise cellular membrane integrity and cause cell lysis.

The published LIPOVELA-V brochure reports sodium deoxycholate raw material purity of 99%. This figure does not identify the concentration of sodium deoxycholate in the finished product.

L-Carnitine and B Vitamins

LIPOVELA-V contains L-carnitine and vitamins B2, B3, and B12, according to its published ingredient information.

L-carnitine participates in the mitochondrial transport of long-chain fatty acids for beta-oxidation. Riboflavin and niacinamide contribute to cellular metabolism through their roles in flavin and nicotinamide coenzyme systems, while vitamin B12 supports several essential metabolic reactions.

These established biochemical functions do not demonstrate that the finished LIPOVELA-V formulation accelerates localized fat metabolism or increases clinical fat-reduction effectiveness.

Glutathione and Antioxidant Components

Glutathione is a naturally occurring tripeptide composed of glutamate, cysteine, and glycine. It participates in intracellular antioxidant defense and reactions involving reactive oxygen species.

The LIPOVELA-V formulation also includes reported antioxidant-related components such as superoxide dismutase (SOD), thioredoxin (TRX), and vitamin C.

Although these ingredients are associated with antioxidant processes, their inclusion does not establish clinically demonstrated skin whitening, prevention of pigmentation, or protection against tissue injury from the finished product.

Growth Factor-Related Ingredients

Published LIPOVELA-V specifications identify epidermal growth factor (EGF), fibroblast growth factor (FGF), and insulin-like growth factor (IGF) among the formulation components.

These signaling proteins are involved in biological processes associated with cell growth, differentiation, and tissue maintenance. Their activity depends on factors such as molecular integrity, concentration, tissue exposure, and the surrounding biological environment.

The presence of growth factor-related ingredients does not independently demonstrate increased collagen production, improved skin elasticity, or clinically meaningful tissue regeneration for LIPOVELA-V.

Multi-Peptide Complex

The published formulation identifies several peptides commonly encountered in cosmetic skin-conditioning products:

• Acetyl Hexapeptide-8: A synthetic cosmetic peptide investigated for its effects on the appearance of expression-related skin lines in selected formulations.
• Palmitoyl Pentapeptide-4: A synthetic peptide studied in topical cosmetic formulations involving skin appearance and extracellular matrix-related pathways.
• Palmitoyl Tetrapeptide-7: A cosmetic peptide investigated for skin-conditioning applications and selected inflammatory signaling pathways.
• Dipeptide Diaminobutyroyl Benzylamide Diacetate: A synthetic peptide used in cosmetic products intended to improve the appearance of expression-related wrinkles.

The biological properties of individual peptides do not establish comparable effects when included in LIPOVELA-V. Product-specific evidence is required to support claims involving skin tightening, wrinkle reduction, or regeneration.

How LIPOVELA-V Is Formulated to Work

LIPOVELA-V combines ingredients associated with different biochemical and physicochemical pathways. Its principal lipolytic components are phosphatidylcholine and sodium deoxycholate, while glutathione, vitamins, peptides, and growth factor-related ingredients contribute to its broader skin-conditioning formulation concept.

Deoxycholate and Cellular Membrane Disruption

Sodium deoxycholate has detergent-like properties that enable it to interact with biological lipid membranes. At sufficient concentrations, this interaction can damage cell membranes and cause cell lysis.

This process is distinct from normal metabolic lipolysis, in which triglycerides stored in adipocytes are enzymatically broken down without necessarily destroying the cells.

Research involving selected deoxycholate-containing injectable formulations has investigated adipocyte destruction and subsequent tissue responses. However, these findings cannot automatically establish equivalent effects or safety for LIPOVELA-V.

Cellular Lipid Metabolism

L-carnitine is involved in transporting fatty acids into mitochondria, while several B vitamins participate in normal metabolic pathways required for cellular energy production.

These mechanisms explain the physiological relevance of the ingredients but do not demonstrate that their inclusion in LIPOVELA-V produces additional localized fat reduction.

Antioxidant and Skin-Conditioning Components

The formulation includes glutathione, vitamin C, peptides, and growth factor-related ingredients that are associated with antioxidant defense, skin conditioning, or cellular signaling in appropriate biological contexts.

The manufacturer-associated brochure positions these ingredients as complementary components intended to support skin appearance during facial contouring applications.

Nevertheless, clinical synergy between the lipolytic ingredients and the skin-conditioning components has not been independently established for the finished LIPOVELA-V formulation.

The mechanisms described in this section concern established properties of individual ingredients and related scientific research. They do not establish product-specific clinical efficacy, treatment duration, or regulatory authorization.

LIPOVELA-V Formulation Characteristics

LIPOVELA-V is commercially distinguished by combining PPC and sodium deoxycholate with glutathione, L-carnitine, vitamins, peptides, and growth factor-related ingredients in a single liquid formulation.

The product is marketed under the concept of V-Line Contour and Glutathione Whitening, emphasizing facial contouring and skin appearance as its principal commercial positioning.

• Lipolytic Ingredient System: Combines PPC and sodium deoxycholate, two substances investigated in localized adipocytolytic formulations.
• Metabolic Support Ingredients: Contains L-carnitine and B vitamins with established roles in cellular metabolic pathways.
• Antioxidant-Related Components: Includes glutathione, vitamin C, superoxide dismutase, and thioredoxin.
• Peptide-Based Skin Conditioning: Incorporates multiple cosmetic peptides and growth factor-related ingredients.

These features describe the composition and commercial positioning of LIPOVELA-V. They should not be interpreted as proof of superior lipolytic activity, reduced adverse reactions, skin whitening, or longer-lasting aesthetic outcomes.

Packaging & Product Presentation

LIPOVELA-V is commercially supplied in individual 5 mL vials. The documented standard packaging contains ten vials, corresponding to a total nominal solution volume of 50 mL per box.

The standard 5 mL × 10-vial configuration is documented in Korean commercial product information and the product's published promotional materials.

Some international distributors also offer individual vials or describe different commercial quantities. Buyers should confirm the exact selling unit and packaging against the supplied product.

LIPOVELA-V should not be confused with LIPOVELA products that omit the V designation. Product names, vial volumes, formulations, and packaging configurations must be verified separately.

Storage & Handling

LIPOVELA-V must be stored according to the original manufacturer-issued labeling. A definitive numerical storage temperature range and validated shelf life have not been established from the available primary product documentation.

• Original Packaging: Keep the product in its supplied packaging until required for its legally permitted use.
• Storage Temperature: Follow the temperature conditions indicated on the original product label.
• Environmental Protection: Avoid conditions that may compromise the formulation or conflict with the manufacturer's handling requirements.
• Container Integrity: Inspect the vial, closure, and packaging for visible damage, leakage, or other signs of compromised integrity.
• Product Traceability: Verify the product name, batch number, expiration date, and manufacturer identification.

Storage recommendations published by third-party distributors may differ. Manufacturer-validated conditions for the specific commercial presentation should take precedence.

Safety & Regulatory Considerations

LIPOVELA-V contains sodium deoxycholate, a substance capable of disrupting biological cell membranes. Products containing cytolytic ingredients require careful professional and regulatory assessment because their effects are not inherently limited to adipocytes.

Potential Tissue Reactions

Potential complications associated with injectable lipolytic products include pain, swelling, bruising, inflammation, infection, persistent nodules, tissue necrosis, scarring, and injury to surrounding anatomical structures.

Facial applications require particular caution because of the complex distribution of nerves, blood vessels, and other sensitive structures.

Multi-Ingredient Formulation

LIPOVELA-V contains numerous ingredients, including botanical or skin-conditioning complexes, peptides, vitamins, and growth factor-related components.

The presence of these substances does not guarantee safety or demonstrate that they prevent inflammation, reduce tissue injury, or improve the tolerability of deoxycholate-based formulations.

Hypersensitivity or other adverse reactions may occur depending on the complete formulation and individual patient characteristics.

Regulatory Authorization

LIPOVELA-V is commercially marketed for facial contouring. However, the product's legal classification, authorized administration route, and approved indications must be established independently for each destination market.

The US Food and Drug Administration has approved specific prescription deoxycholic acid products for defined indications. Such approvals do not extend automatically to LIPOVELA-V or other formulations containing related ingredients.

US FDA approval for LIPOVELA-V has not been established. Commercial availability in South Korea or international distribution channels does not demonstrate authorization for injection in another jurisdiction.

This information is intended for professional product identification and commercial evaluation. It does not constitute treatment guidance, establish individual suitability, or authorize the injection of an unapproved product.

Frequently Asked Questions